15 October 2021 - First PBAC recommendation for a new gene therapy.

Recommendations made by the PBAC at its September 2021 intracycle meeting have been published.

The PBAC recommended the following technologies:

• Dapagliflozin (Forxiga) - new indication (heart failure)
• Methoxsalen (Uvadex) - new indication
• Nintedanib esylate (Ofev) - new indication
• Onasemnogene abeparvovec (Zolgensma) - new gene therapy
• Choriogonadotropin alfa (Ovidrel) - new formulation
• Doxorubicin hydrochloride (pegylated, liposomal) (Caelyx) - restriction change
• Raltitrexed (Tomudex) - Restriction change
• Rituximab (Riximyo, Truxima) - Restriction change
• Romosozumab (Evenity) - Restriction change
• Teriparatide (Forteo) - Restriction change
• Somatropin (multiple brands) - Restriction change
• Tocilizumab (Actemra) - New temporary listing

The PBAC rejected the following medicines:

• Dapagliflozin (Forxiga) - new indication (chronic kidney disease)
• Tafamidis (Vyndamax) - new medicine

Read PBAC outcomes (September 2021)